Orforglipron is Eli Lilly's small-molecule, non-peptide GLP-1 receptor agonist — the first true oral GLP-1 cleared for obesity, branded as Foundayo. Unlike semaglutide and tirzepatide, orforglipron requires no fatty-acid modification and no peptide-stabilizing matrix to survive the gut. The molecule is primarily hepatically metabolized; the label warns against use in severe hepatic impairment, but mild-to-moderate liver impairment is allowed at the standard dose.
The ACHIEVE Phase 3 program covered type-2 diabetes (ACHIEVE-1, ACHIEVE-2), obesity (ACHIEVE-3, ACHIEVE-4), and adjacent indications. The FDA approved the obesity indication in April 2026. Indirect comparisons against oral semaglutide and oral Wegovy have been mixed: orforglipron leads on HbA1c, oral semaglutide may lead on weight loss. By the April 30 Q1 2026 call, roughly 20,000 patients were on the drug, more than 8,000 prescribers had written it, and Lilly confirmed commercial access at two of the three largest US PBMs effective mid-May. On May 4, an FAERS hepatic-failure case logged April 30 surfaced publicly — Lilly's Global Patient Safety team called the event 'not reasonably related to Foundayo,' and the company released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program.
The small-molecule approach carries pricing and manufacturing implications the peptide GLP-1 economy does not — CDMO capacity stops being the bottleneck, and small-molecule generics will eventually follow a different cost curve. Stories here cover trial readouts, post-launch tracking, and competing oral programs.
Lilly presented the Phase 3 ACHIEVE-4 trial of its oral small-molecule GLP-1 drug Foundayo (orforglipron) at EASD on Thursday, October 1, 2026, alongside publication in The Lancet. In 2,749 adults with type 2 diabetes, overweight or obesity, and increased cardiovascular risk, Foundayo met its noninferiority goal against insulin glargine for cardiovascular death, heart attack, stroke, or hospitalization for unstable angina (MACE-4 hazard ratio 0.84; 95% CI 0.59 to 1.20); the three-part MACE-3 hazard ratio was 0.77 (95% CI 0.52 to 1.13). At 52 weeks, A1C fell 1.6 points versus 1.0 and weight fell 8.8% versus a 1.7% gain on glargine. Lilly also reported a lower rate of death from any cause (hazard ratio 0.43) but described that analysis as exploratory and not controlled for multiple comparisons; 10.6% of Foundayo patients stopped treatment because of adverse events.
Lilly announced on Tuesday, September 29, 2026 an indirect treatment comparison, presented at EASD, of its oral small-molecule GLP-1 drug Foundayo (orforglipron) 17.2 mg against Novo's oral semaglutide 25 mg in adults with type 2 diabetes, using data from Lilly's ACHIEVE-3 trial and Novo's PIONEER PLUS trial. At 52 weeks, Foundayo was associated with 1.5 percentage points more weight loss (95% CI -2.7 to -0.2) and a 0.3-point larger A1C reduction (95% CI -0.6 to -0.1); sensitivity analyses gave 1.5 to 2.4 points and 0.3 to 0.6 points. Lilly's Rachel Batterham said head-to-head trials give the best comparison of two medicines, and the two drugs have not been tested directly against each other at these doses.
The oral GLP-1 launch race entered its ninth month with Novo Nordisk's Wegovy pill (oral semaglutide 25 mg for chronic weight management, U.S. launch January 5, 2026) reaching approximately 183,000 weekly total scripts per the most recent IQVIA week ending September 5, 2026 — the highest weekly total since launch. Eli Lilly's Foundayo (orforglipron, once-daily oral small-molecule non-peptide GLP-1 receptor agonist, U.S. launch April 2026) continued its own prescription climb through the same reporting window. Both products are indicated for adults with obesity or overweight with weight-related comorbidities. Wegovy pill's climb reflects continued Medicare Part D coverage expansion following the November 2025 pricing agreement (Ozempic Pill / Wegovy pill at $149/month per the deal) and CMS 2026 formulary guidance. Foundayo pricing on TrumpRx and cash-pay LillyDirect anchors at $149/month at starting doses. The concurrent oral launch trajectories are the largest test to date of oral incretin adoption relative to the established weekly-injectable class dominated by injectable Wegovy and Zepbound.
Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a triple agonist (GLP-1, GIP, and glucagon receptor) peptide for obesity being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide competes mechanistically with Eli Lilly's retatrutide (once-weekly injectable triple agonist, roughly 28.7% weight loss at 68 weeks in Phase 3 TRIUMPH-4) in the triple-agonist class. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.
Eli Lilly (NYSE: LLY) reported Q2 2026 earnings Wednesday August 5, 2026 with revenue of $23 billion (+48% year-over-year), well ahead of analyst consensus of $20.5 billion. Full-year 2026 revenue guidance was raised to $85-87 billion from the prior $82-85 billion range. Mounjaro (tirzepatide for type 2 diabetes) revenue rose 91% to $9.9 billion, split $4.8 billion US and $5.2 billion international, with the international majority driven by aggregate international Mounjaro market share now above 50% per prior Lilly executive commentary. Zepbound (tirzepatide for obesity) delivered $4.9 billion in US revenue (+44% year-over-year), with strong prescription-volume growth more than offsetting the low-to-mid-teens price erosion Lilly had guided to for FY26. Foundayo (orforglipron, the first oral small-molecule GLP-1 receptor agonist approved by FDA in April 2026) generated $98 million in its first fully operational commercial quarter, providing the first commercial-earnings-line view of the oral small-molecule GLP-1 category. Combined Mounjaro + Zepbound franchise revenue reached $14.9 billion, representing approximately 65% of total Lilly revenue for the quarter. LLY shares rose approximately 4% intraday on the earnings and guidance beat. Analyst commentary flagged the substantial widening of the Lilly-Novo obesity franchise gap.
Eli Lilly (NYSE: LLY) reports Q2 2026 earnings Wednesday August 5, 2026 before market open with analyst consensus at $20.5 billion revenue and $7.74 EPS. Primary analyst focus numbers: Foundayo (orforglipron) weekly prescription volumes near 20,000 as the initial commercial ramp indicator following the April 2026 FDA approval as the first oral small-molecule non-peptide GLP-1 receptor agonist; Mounjaro (tirzepatide, type 2 diabetes indication) and Zepbound (tirzepatide, obesity indication) sales trajectory (Q1 2026 combined revenue $12.82 billion, approximately 65% of Lilly total revenue, driven by U.S. commercial volume plus international expansion with aggregate international Mounjaro market share now north of 50% per Lilly executive commentary at Goldman Sachs Healthcare Conference); full-year 2026 revenue guidance currently at $83-85 billion for potential revision; and the international pricing pressure headwind with management guiding low-to-mid-teens price erosion for FY26. Novo Nordisk reports H1 2026 results the same Wednesday August 5. Wegovy pill (oral semaglutide 25 mg for obesity) Q1 2026 sales of approximately $354 million provide the H1 baseline for the Novo pill franchise; injectable Wegovy Q1 2026 sales were $18.2 billion Danish kroner (+12% YoY).
The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.
Q2 2026 earnings season for the peptide-and-obesity big three opens next week. Merck reports Tuesday August 4 at 9:00 AM ET with the LIPFENDRA (enlicitide) FDA approval milestone (July 16) roughly one week old at report time; analyst focus areas include the pricing strategy at $10.50 per tablet ($315 per 30-day supply), the pharmacy-benefit distribution model, and initial payer coverage momentum. Eli Lilly reports Wednesday August 5 before market open; analyst focus areas include Foundayo (orforglipron) first-quarter-out US retail sales (Q1 sales were not yet in the books at the last report), Mounjaro and Zepbound growth versus the Wegovy pill franchise, and TRIUMPH-2 and TRIUMPH-3 readouts for retatrutide expected later in 2026. Novo Nordisk reports Thursday August 6; analyst focus areas include the Wegovy pill uptake beyond the 3 million-prescription milestone documented at ADA 2026 (June), the impact of Novo's price cuts in China and India, the Vivani implant partnership announced July 7, and the response to analyst concerns about the January 2027 Wegovy list price reset to $675 (a 50% cut from current levels). The three earnings prints together are expected to frame the second-half 2026 obesity market trajectory and the competitive positioning of the incretin, amylin, and macrocyclic peptide franchises against each other.
Fierce Pharma's weekly Oral GLP-1 Tracker, which leverages IQVIA data and analyst notes, reports that Eli Lilly's Foundayo (orforglipron) reached 19,879 US prescriptions in its ninth week of retail launch compared with 159,000 for Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) in its 22nd week. Foundayo received FDA approval April 1, 2026 and began retail shipments through LillyDirect on April 6; the Wegovy pill received FDA approval December 22, 2025 and launched in early January 2026. Adjusting for launch timing, Foundayo tracks numerically behind Wegovy pill at equivalent weeks, though Lilly executives noted on the Q1 earnings call that Foundayo's first-week pace ran ahead of the Zepbound injectable launch (2024). Spherix Global Insights analysis attributes Wegovy pill's uptake advantage to first-mover positioning and physician familiarity with the Wegovy brand name established through the injectable franchise. Foundayo's Q2 sell-in run rate implies roughly $146 million in Q2 revenue and $1.6 billion for full-year 2026 by analyst modeling.
Lilly presented full Phase 3 data from the ACHIEVE program in type 2 diabetes at ADA 2026's Monday symposium. In the head-to-head ACHIEVE-3 trial, Foundayo (orforglipron) beat oral semaglutide across the primary and all key secondary endpoints, with 37.1% of patients on the highest Foundayo dose reaching HbA1c under 5.7% (normal range) versus 12.5% on the highest oral semaglutide dose tested. ACHIEVE-2 compared Foundayo to dapagliflozin; ACHIEVE-5 added it to insulin glargine. Lilly plans to submit Foundayo for FDA T2D approval by end of Q2 under the Commissioner's National Priority Voucher.
Monday's data sharpened the oral GLP-1 competitive map. Lilly's Foundayo (orforglipron) leads with a Phase 3 head-to-head win over oral semaglutide and a Q2 FDA filing pending. Structure's aleniglipron sits closest, with 16.3% Phase 2b weight loss and Nature Medicine publication on Friday. AstraZeneca's elecoglipron just cleared Phase 2b. Chinese entrants Hengrui-Kailera (ribupatide, HRS-7535) added Phase 2 and 3 readouts. Novo's Wegovy pill remains the only currently-approved oral, but the next-wave field is now broad and head-to-head data are arriving fast.
The 86th ADA Scientific Sessions opened June 5 in New Orleans with the late-breaker embargo lifting at 6:30 p.m. CT. Saturday's June 6 Phase 3 retatrutide symposium brings full TRIUMPH-1 (28.3% mean weight loss at 80 weeks) and TRANSCEND-T2D-1 data; Monday's June 8 orforglipron ACHIEVE symposium covers head-to-head data against oral semaglutide and dapagliflozin; Roche, Novo Nordisk, and Boehringer all run investor events the same day.
The American Diabetes Association's 86th Scientific Sessions run June 5-8, with a Phase 3 retatrutide symposium June 6 (TRIUMPH-1 and TRANSCEND-T2D-1) and a Foundayo/orforglipron symposium June 8. Beyond Lilly and Novo, the oral-incretin race fills the program: Structure's aleniglipron, Hengrui and Kailera's oral GLP-1/GIP ribupatide (up to 12.1% in Phase 2), and Boehringer/Zealand's survodutide SYNCHRONIZE-1 in obesity. More than 12,000 attendees are expected.
The American Diabetes Association's 86th Scientific Sessions open June 5-8 with the year's deepest metabolic-peptide slate. Lilly presents full TRIUMPH-1 obesity data and the first retatrutide diabetes Phase 3, TRANSCEND-T2D-1, plus the orforglipron ACHIEVE program comparing the oral GLP-1 against dapagliflozin, oral semaglutide, and placebo. Innovent's mazdutide brings GLORY-2 and the DREAMS-3 head-to-head versus semaglutide, AstraZeneca's eleglipron carries full Phase 2b data, and Lilly's GLP-1/GIP/glucagon/amylin/calcitonin quintuple agonist takes a plenary slot.
Eli Lilly will present full data on retatrutide, Foundayo (orforglipron), and Mounjaro at the American Diabetes Association's 86th Scientific Sessions. The triple agonist retatrutide lowered A1C by up to 2.0% and drove 16.8% weight loss, about 36.6 lbs at the 12 mg dose, over 40 weeks in its first Phase 3 diabetes trial, TRANSCEND-T2D-1. Oral Foundayo beat oral semaglutide head-to-head with 73.6% greater relative weight loss and an A1C reduction of up to 1.7% against 0.8% for dapagliflozin.
Published May 12 in Nature Medicine and presented at ECO 2026, the first-of-its-kind ATTAIN-MAINTAIN trial (NCT06584916) tested whether adults who had already lost substantial weight on Wegovy or Zepbound could maintain it after switching to once-daily orforglipron. Over 52 weeks, the semaglutide-switch group regained an average of 1 kg and the tirzepatide-switch group an average of 5 kg, with most cardiometabolic gains preserved. Carel le Roux and Louis Aronne led the analysis.
IQVIA's weekly prescription tracker for Foundayo (orforglipron) hit approximately 17,000 prescriptions for the week ending May 15, 2026, per Citi's Friday client note — Lilly's first above-15,000 weekly print since the April 6 launch. The week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5), and ~17,000 in the new print. Novo Nordisk's Wegovy pill recorded roughly 142,000 prescriptions in the same week — the trajectory gap is narrowing as Foundayo's PBM coverage activates at the largest US plans but still remains 8.3x the Foundayo volume. Citi maintains $146M Foundayo Q2 revenue and $1.6B 2026 full-year estimates; the IQVIA print supports the trajectory. Lilly's late-May TV-advertising launch may amplify the next leg of Foundayo growth heading into mid-June.
The CNBC May 18 piece surfaced explicit company-supported positioning that Foundayo (orforglipron) and oral Wegovy are targeting different patient segments rather than competing head-to-head. Novo's framing for Wegovy pill is 'injectable-like efficacy' in oral form, with the Phase 3 OASIS-MAINTAIN data anchoring approximately 15% mean weight loss. Lilly's framing for Foundayo positions it as more of a 'starter' GLP-1 — lower weight-loss ceiling (around 11.2% in ATTAIN-1) but no food-or-water dosing restrictions and a non-peptide small-molecule manufacturing path that supports a lower long-term price. Both companies say the pills are expanding the market rather than significantly cannibalizing demand for the injectables — a different framing than the 'oral-disrupts-injectable' narrative that dominated 2025 coverage. The market-expansion hypothesis will be testable as ADA 2026 (June 5-8) and Q2 2026 earnings prints land.